Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

Recruiting now · Phase 1/Phase 2

Conditions studied: Metastatic Prostate Cancer

In brief

The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.

Key facts

Study ID
NCT07181161
Run by
AstraZeneca
People needed
177
Starts
2025-10-01
Expected to finish
2029-01-18
Last updated by the study team
2026-07-15

Who can join

Age: 18 and older, up to 130. Sex: male. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.